Amylin
Amylin (IAPP) is a 37-aa peptide co-secreted with insulin by beta cells that suppresses glucagon, slows gastric emptying, and reduces food intake. Deficient in T1D and late T2D. Pramlintide is its FDA-approved synthetic analogue.
Community Rating
No ratings yet
Compound Profile
Amylin
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Amylin is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Suppresses postprandial glucagon secretion by approximately 50% — reduces hepatic glucose output post-meal
- Slows gastric emptying rate — blunts postprandial glucose spike by regulating nutrient absorption speed
- Reduces food intake via area postrema and nucleus tractus solitarius (NTS) in the brainstem
- Amylin is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Suppresses postprandial glucagon secretion by approximately 50% — reduces hepatic glucose output post-meal
- Slows gastric emptying rate — blunts postprandial glucose spike by regulating nutrient absorption speed
- Reduces food intake via area postrema and nucleus tractus solitarius (NTS) in the brainstem
- Complementary to insulin — together they create the complete postprandial neuroendocrine response
In Plain English
Simple summaryAmylin is a 37-amino acid peptide co-secreted with insulin by pancreatic beta cells at every meal -- in a 1:100 molar ratio with insulin. It was discovered in 1987 when researchers noticed a protein deposit in the pancreatic islets of Type 2 diabetes patients that turned out to be amyloid formed from aggregated amylin. In healthy individuals, amylin's job is to complement insulin: while insulin handles glucose transport into cells, amylin slows gastric emptying (reducing the rate of glucose absorption), suppresses postprandial glucagon release, and signals the brain to stop eating. In Type 1 diabetes, beta cells are destroyed and amylin secretion ceases completely along with insulin. In Type 2 diabetes, amylin secretion is significantly impaired. This dual deficiency -- missing both insulin and amylin -- is why pramlintide (synthetic amylin) was developed.
- Suppresses postprandial glucagon secretion by approximately 50% — reduces hepatic glucose output post-meal
- Slows gastric emptying rate — blunts postprandial glucose spike by regulating nutrient absorption speed
- Reduces food intake via area postrema and nucleus tractus solitarius (NTS) in the brainstem
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Amylin?
Tap any underlined term for an instant definition.
Amylin (Islet Amyloid Polypeptide, IAPP) is a 37-amino acid peptide synthesized and co-secreted with insulin by pancreatic beta cells in a 1:100 molar ratio to insulin. It was first identified in 1987 in amyloid deposits isolated from the islets of Langerhans in type 2 diabetic patients (Westermark et al., Cooper et al.).
Amylin acts on the amylin receptor complex (a heterodimer of calcitonin receptor + RAMP proteins, particularly RAMP1/3) in the area postrema, the brainstem, and hypothalamus. Via these receptors it
- **Suppresses postprandial glucagon**: Reduces alpha-cell glucagon secretion by 40-60%, limiting hepatic glucose output after meals
- **Slows gastric emptying**: Creates a "brake" on the rate of nutrient delivery to the small intestine, smoothing glucose absorption kinetics
- **Reduces food intake**: Acts centrally via area postrema → NTS → arcuate nucleus to induce satiety independent of leptin
- **Modulates bone turnover**: Amylin/calcitonin receptor overlap means amylin has weak bone-anabolic properties
Amylin deficiency is complete in type 1 diabetes (total beta cell loss) and progressive in late type 2 diabetes (beta cell failure). This amylin deficit is why insulin therapy alone produces suboptimal glycemic control — the full postprandial hormonal response requires both insulin and amylin.
The pathological side of amylin is its tendency to misfold and aggregate into insoluble amyloid fibrils in islet tissue — a key finding in type 2 diabetes pathology. Human IAPP is approximately 100x more prone to fibrillation than rodent IAPP (which has several proline substitutions blocking aggregation). Pramlintide reproduces rodent IAPP's proline substitution pattern to create a stable, clinically usable amylin analogue.
Research applications include: T1D/T2D adjunct therapy research, obesity and satiety studies, islet amyloid toxicity research, and incretin axis investigations.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Amylin. See all Metabolic & Weight peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Amylin is primarily used as a research reference standard in studies of islet biology, gastric emptying, glucagon regulation, and appetite. IV infusion at 4-8 pmol/kg/min has been used in acute human studies to assess its effects on glycemia and appetite.
For clinical research, pramlintide (the synthetic non-aggregating analogue) has replaced native amylin: - Type 1 diabetes: 15-60 mcg SC before meals - Type 2 diabetes: 60-120 mcg SC before meals
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Research tool for in vitro islet studies, in vivo gastric emptying studies, and central appetite research. Pramlintide (stable analogue) is used in clinical and translational research.
What the research doesn't show
Native amylin has a serious problem beyond its biological role: it's highly prone to forming cytotoxic amyloid fibrils, which is why it was initially discovered in diabetes pancreatic deposits. This amyloidogenic property is exactly what required engineering in pramlintide and cagrilintide -- subtle changes to prevent aggregation while preserving biological activity. The amyloid angle also connects amylin biology to broader protein aggregation research in neurodegenerative disease.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Amylin, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Amylin has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: suppresses postprandial glucagon secretion by approximately 50% — reduces hepatic glucose output post-meal.
The most commonly reported side effect in research subjects is native amylin aggregates into islet amyloid plaques — relevant to research on islet inflammation. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Pramlintide (Symlin) is the currently approved synthetic amylin for clinical use. Cagrilintide is the next-generation long-acting amylin analogue in late-stage development. Oxyntomodulin and PYY are other postprandial satiety hormones released from different gut cells (L-cells rather than pancreatic beta cells). Understanding amylin gives essential context for why cagrilintide's combination with semaglutide is being pursued.
Compare Amylin side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.